Safety and Dosing Study of Glucagon-Like Peptide 2 in Children With Intestinal Failure

Abstract

Background and Aims: A glucagon-like peptide 2 (GLP-2) analogue is approved for adults with intestinal failure, but no studies of GLP-2 have included children. This study examined the pharmacokinetics, safety, and nutritional effects of GLP-2 in children with intestinal failure. Methods: Native human GLP-2(1-33) was synthesized following good manufacturing practices. In an open-label trial, with parental consent, 7 parenteral nutrition–dependent pediatric patients were treated with subcutaneous GLP-2 (20 µg/kg/d) for 3 days (phase 1) and, if tolerated, continued for 42 days (phase 2). Nutritional treatment was directed by the primary caregivers. Patients were followed to 1 year. Results: Seven patients were enrolled (age: 4.0 ± 0.8 years; bowel length, mean ± SEM: 24% ± 4% of predicted). All were parenteral nutrition dependent since birth, receiving 44% ± 5% of calories by parenteral nutrition. GLP-2 treatment had no effect on vital signs (blood pressure, heart rate, and temperature) and caused no significant adverse events. Peak GLP-2 levels were 380 pM (day 3) and 295 pM (day 42), with no change in half-life or endogenous GLP-2 levels. Nutritional indices showed a numeric improvement in z scores and citrulline levels; the z score was maintained while citrulline levels returned to baseline once GLP-2 was discontinued. Conclusions: GLP-2 was well tolerated in children, with a pharmacokinetic profile similar to that of adults. There were no changes in endogenous GLP-2 release or metabolism. These results suggest that GLP-2 ligands may be safely used in pediatric patients; larger trials are suggested to investigate nutritional effects.

Keywords

pharmacokinetics necrotizing enterocolitis adaptation dipeptidyl peptidase IV

Get full access to this article

View all access options for this article.

References

Dudrick

Wilmore

Vars

Rhoads

JE.

Long-term total parenteral nutrition with growth, development, and positive nitrogen balance. Surgery. 1968;64(1):134-142.

Kocoshis

SA.

Medical management of pediatric intestinal failure. Semin Pediatr Surg. 2010;19(1):20-26.

Squires

Duggan

Teitelbaum

. Natural history of pediatric intestinal failure: initial report from the Pediatric Intestinal Failure Consortium. J Pediatr. 2012;161(4):723-728.

Martin

Beck

Sigalet

DL.

Gut hormones, and short bowel syndrome: the enigmatic role of glucagon-like peptide-2 in the regulation of intestinal adaptation. World J Gastroenterol. 2006;12(26):4117-4129.

Orskov

Holst

Knuhtsen

Baldissera

Poulsen

Nielsen

OV.

Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467-1475.

Brubaker

Anini

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol. 2003;81(11):1005-1012.

Drucker

Yusta

Physiology and pharmacology of the enteroendocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014;76:561-583.

Meier

Nauck

Pott

. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology. 2006;130(1):44-54.

Martin

Wallace

Hartmann

. Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2005;288(3):G431-G438.

10.

Martin

Wallace

Sigalet

DL.

Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 2004;286(6):G964-G972.

11.

Sangild

Tappenden

Malo

. Glucagon-like peptide 2 stimulates intestinal nutrient absorption in parenterally fed newborn pigs. J Pediatr Gastroenterol Nutr. 2006;43(2):160-167.

12.

Suri

Turner

Sigalet

. Exogenous glucagon-like peptide-2 improves outcomes of intestinal adaptation in a distal-intestinal resection neonatal piglet model of short bowel syndrome. Pediatr Res. 2014;76(4):370-377.

13.

Jeppesen

Sanguinetti

Buchman

. Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients. Gut. 2005;54(9):1224-1231.

14.

Jeppesen

Pertkiewicz

Messing

. Teduglutide reduces need for parenteral support among patients with short bowel syndrome with intestinal failure. Gastroenterology. 2012;143(6):1473-1481.

15.

Jeppesen

Lund

Gottschalck

. Short bowel patients treated for two years with glucagon-like peptide 2: effects on intestinal morphology and absorption, renal function, bone and body composition, and muscle function. Gastroenterol Res Pract. 2009;2009:616054.

16.

Amin

Holst

Hartmann

Wallace

Wright

Sigalet

DL.

Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate. Pediatrics. 2008;121(1):e180-e186.

17.

Sigalet

Martin

Meddings

Hartman

Holst

JJ.

GLP-2 levels in infants with intestinal dysfunction. Pediatr Res. 2004;56(3):371-376.

18.

Sigalet

de Heuvel

Wallace

. Effects of chronic glucagon-like peptide-2 therapy during weaning in neonatal pigs. Regul Pept. 2014;188:70-80.

19.

Hartmann

Johnsen

Orskov

Adelhorst

Thim

Holst

JJ.

Structure, measurement, and secretion of human glucagon-like peptide-2. Peptides. 2000;21(1):73-80.

20.

Hartmann

Harr

Jeppesen

. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endo Metab. 2000;86:2884-2888.

21.

Holst

JJ.

Glucagon and glucagon-like peptides 1 and 2. Results Probl Cell Differ. 2010;50:121-135.

22.

Bailly-Botuha

Colomb

Thioulouse

. Plasma citrulline concentration reflects enterocyte mass in children with short bowel syndrome. Pediatr Res. 2009;65(5):559-563.

23.

Peretti

Loras-Duclaux

Kassai

. Growth hormone to improve short bowel syndrome intestinal autonomy: a pediatric randomized open-label clinical trial. JPEN J Parenter Enteral Nutr. 2011;35(6):723-731.

24.

Sigalet

Boctor

Brindle

Lam

Robertson

Elements of successful intestinal rehabilitation. J Pediatr Surg. 2011;46(1):150-156.